Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9320759 | European Urology Supplements | 2005 | 8 Pages |
Abstract
All three tamsulosin OCAS doses tested were effective in relieving urinary symptoms and improving disease-specific quality of life in LUTS/BPH patients. The 0.8Â mg and, in particular, the 0.4Â mg doses were better tolerated than the 1.2Â mg dose. Therefore, these two doses were selected for further evaluation in a phase 3a placebo- and comparator (tamsulosin modified release capsules) controlled trial.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Christopher R. Chapple, Jerzy Lorenz, Raymond Mortensen, Harald Pauthner, Mario O. Reis, Claude C. Schulman, Ingrid van der Putten-Slob,